Synonyms: chidamide | CS-055 | CS055 | Epidaza® (China) | HBI-8000
tucidinostat is an approved drug (China)
Compound class:
Synthetic organic
Comment: Tucidinostat (chidamide) is an orally active inhibitor of histone deacetylase (HDAC) enzymes [4]. It has some subtype selectivity for HDAC isoenzymes 1, 2, 3 and 10. Note that we show this compound with no specified stereochemistry.
|
|
References |
1. Dong M, Ning ZQ, Xing PY, Xu JL, Cao HX, Dou GF, Meng ZY, Shi YK, Lu XP, Feng FY. (2012)
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol, 69 (6): 1413-22. [PMID:22362161] |
2. Gong K, Xie J, Yi H, Li W. (2012)
CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J, 443 (3): 735-46. [PMID:22339555] |
3. Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C et al.. (2019)
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 20 (6): 806-815. [PMID:31036468] |
4. Liu L, Chen B, Qin S, Li S, He X, Qiu S, Zhao W, Zhao H. (2010)
A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun, 392 (2): 190-5. [PMID:20060381] |
5. Qiao Z, Ren S, Li W, Wang X, He M, Guo Y, Sun L, He Y, Ge Y, Yu Q. (2013)
Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. Biochem Biophys Res Commun, 434 (1): 95-101. [PMID:23541946] |
6. Wang H, Guo Y, Fu M, Liang X, Zhang X, Wang R, Lin C, Qian H. (2012)
Antitumor activity of Chidamide in hepatocellular carcinoma cell lines. Mol Med Rep, 5 (6): 1503-8. [PMID:22484326] |
7. Yao Y, Zhou J, Wang L, Gao X, Ning Q, Jiang M, Wang J, Wang L, Yu L. (2013)
Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS ONE, 8 (8): e70522. [PMID:23940586] |